The first and only fully human il-17a antagonist.secukinumab is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy- and is indicated for the treatment of adult patients with active psoriatic arthritis - and is indicated for the treatment of adult patients with active ankylosing spondylitis.
Voir plus de détails